Probiotic modulation of gut microbiota with Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum CCFM8661 mitigates recurrent respiratory infections.
Probiotic modulation of gut microbiota with Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum CCFM8661 mitigates recurrent respiratory infections in children: a randomised-controlled trial.
AI Summary
Key Findings
Abstract
BACKGROUND: Recurrent respiratory tract infections (RRTIs) in children are associated with substantial morbidity and healthcare burden. Modulation of the gut microbiota via probiotics represents a potential adjunctive strategy to prevent recurrent infections. This study evaluated the efficacy and safety of Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum CCFM8661 in children with RRTIs. METHODS: In a double-blind, randomized, placebo-controlled trial, 120 children with RRTIs received either daily probiotic supplementation (1 × 10CFU/day; n = 60) or placebo (n = 60) for 3 months, with a 6-month follow-up. Primary outcome was clinical efficacy; secondary outcomes included gut microbiota composition (16 S rRNA sequencing) and plasma immune biomarkers (IgA, IgG, IgM, C3, C4). RESULTS: Probiotics significantly improved clinical efficacy compared with placebo in both per-protocol [82.1% vs. 64.2%, p = 0.033] and intention-to-treat analyses [76.7% vs. 56.7%, p = 0.020]. Children in the probiotic group experienced fewer and shorter respiratory episodes, including fever, cough, and pharyngeal congestion (all p
Affiliation
Ke Chen
External References
- PubMed ID:
- 42090020
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.